The European Commission has approved its seventh Advanced Purchase Agreement (APA) with a pharmaceutical company to ensure access to a potential vaccine against COVID-19 in Q4 of 2021 and in 2022.
Under this contract, Member States will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for 100 million additional doses over the course of 2021, 2022, and 2023, once reviewed and approved by EMA as safe and effective. Member States will also be able to donate vaccines to lower and middle-income countries or to re-direct them to other European countries.
This contract complements an already broad portfolio of vaccines to be produced in Europe, including the contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Moderna and the concluded exploratory talks with Valneva. It represents another key step towards ensuring that Europe is well prepared to face the COVID-19 pandemic.
Novavax
Novavax is a biotechnology company developing next-generation vaccines for serious infectious diseases. Their COVID-19 vaccine is already under rolling review by EMA in view of a potential market authorisation.
The Commission has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the company’s experience in vaccine development and its production capacity to supply the whole of the EU.
Leave a Reply